In silico transcriptome-based drug screening identifies celastrol as a multi-species therapeutic agent against aging-related sarcopenia and mitochondrial dysfunction | Synapse
March 3, 2026Open Access
In silico transcriptome-based drug screening identifies celastrol as a multi-species therapeutic agent against aging-related sarcopenia and mitochondrial dysfunction
Puntos clave
Celastrol acts as a pharmacological mimetic, promoting mitochondrial rejuvenation, which is crucial for muscle health.
Findings indicate celastrol enhances muscle function and combats sarcopenia across different species, including humans.
Analysis involved transcriptome data to discover celastrol's potential benefits as a therapeutic agent.
These results highlight an innovative approach to treating age-related muscle decline, requiring further exploration.
Resumen
Collectively, these findings suggest celastrol as apharmacological mimetic of exercise-induced mitochondrial rejuvenation, offering a translatable strategy to combat age-related muscle decline.